ASP Isotopes Inc.

ASP Isotopes Inc.(ASPI)の株式分析

$3.880

-0.154 (-3.96%)終値時点

Loading chart…
High
4.110
Open
4.050
VWAP
3.95
Vol
2.76M
Mkt Cap
157.36M
Low
3.860
Amount
10.89M
EV/EBITDA, TTM
-1.18

ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. Its proprietary technologies, the Aerodynamic Separation Process and Quantum Enrichment technology, are designed to enable the production of isotopes used in several industries. Its initial focus is on the production and commercialization of enriched Carbon-14 (C-14), Silicon-28 (Si-28) and Ytterbium-176 (Yb-176). It is also a provider of liquid helium with operations at the Virginia Gas Project in South Africa. Its nuclear fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its specialist isotopes and related services segment is focused on research and development of technologies and methods used to separate isotopes for highly specialized target end markets.

AI analysis of ASP Isotopes Inc. (ASPI)

hold

Currently, ASP Isotopes Inc is not a strong buy. The stock is priced at $3.88, which is significantly down 55.25% over the past year. The RSI is at 39.43, indicating it is nearing oversold territory, but the forward P/E ratio is very high at 54.35, suggesting that the stock may be overvalued based on future earnings expectations. Additionally, the company reported a net income loss of $33,993,000 in Q2 2026, which raises concerns about profitability. The main risk is the high forward P/E ratio, indicating potential overvaluation in the current market context.

バリュエーション指標

The current forward P/E ratio for ASP Isotopes Inc. (ASPI) is 54.35, compared to its 5-year average forward P/E of -3.98.

Forward P/E

Overvalued
5Y Average P/E
-3.98
Current P/E
54.35
割高
30.05
割安
-38.00

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-2.66
Current EV/EBITDA
-1.18
割高
31.45
割安
-36.77

Forward P/S

Fair
5Y Average P/S
14.23
Current P/S
7.21
割高
24.66
割安
3.81

Whales holding ASPI

E

Encompass Capital Advisors LLC

+ HoldingASPI

-4.90%

3M Return

イベントタイムライン

2026-08-20 (ET)

09:30:00

ASP Isotopes Subsidiary Tetra4 Starts Liquid Helium Plant Commissioning

2026-07-21 (ET)

09:30:00

ASP Isotopes Subsidiary Signs Uranium Hexafluoride Research Agreement

2026-07-16 (ET)

17:30:00

ASP Isotopes Files to Sell 23.16M Shares of Common Stock

2026-07-15 (ET)

18:30:00

ASP Isotopes Enters Private Exchange Agreements for $109.2M in Notes

2026-06-25 (ET)

10:00:00

ASP Isotopes and ENDRA to Merge, Raising $50 Million

ニュース

ASPI FAQ — answered by Alphio AI

ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. Its proprietary technologies, the Aerodynamic Separation Process and Quantum Enrichment technology, are designed to enable the production of isotopes used in several industries. Its initial focus is on the production and commercialization of enriched Carbon-14 (C-14), Silicon-28 (Si-28) and Ytterbium-176 (Yb-176). It is also a provider of liquid helium with operations at the Virginia Gas Project in South Africa. Its nuclear fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its specialist isotopes and related services segment is focused on research and development of technologies and methods used to separate isotopes for highly specialized target end markets. It operates in the Healthcare sector (MISCELLANEOUS CHEMICAL PRODUCTS industry).

Currently, ASP Isotopes Inc is not a strong buy. The stock is priced at $3.88, which is significantly down 55.25% over the past year. The RSI is at 39.43, indicating it is nearing oversold territory, but the forward P/E ratio is very high at 54.35, suggesting that the stock may be overvalued based on future earnings expectations. Additionally, the company reported a net income loss of $33,993,000 in Q2 2026, which raises concerns about profitability. The main risk is the high forward P/E ratio, indicating potential overvaluation in the current market context.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める